Iritero 40 Mg/2 Ml, 100 Mg/5 Ml & 300 Mg/15 Ml 40 mg, 100 mg, 300 mg Solution for infusion
PDF Leaflet Revision Date: 11 July 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of advanced colorectal cancer.
Dosage (summary)
350 mg/mu00b2 IV every 3 weeks; 80 mg/mu00b2 weekly or 180 mg/mu00b2 every 2 weeks in combination with 5-FU/FA.
Special Populations
- Hepatic impairment
- Elderly
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation.
Key Drug Interactions
- Azole antifungals
- St. John's Wort
- CYP3A4 inducers/inhibitors
Contraindications
- Severe hypersensitivity to irinotecan
- Chronic inflammatory bowel disease
- Bilirubin > 1.5 times ULN
- Severe bone marrow failure
- WHO performance status > 2
Common side effects
- Diarrhoea
- Nausea
- Vomiting
- Neutropenia
- Alopecia
Counselling Points
- Avoid pregnancy during treatment
- Stay hydrated and manage diarrhoea promptly
- Report any signs of infection immediately
Serious warnings
- Risk of severe neutropenia
- Delayed diarrhoea can be life-threatening
- Use in specialized units only
Important Disclaimer
The Iritero 40 Mg/2 Ml, 100 Mg/5 Ml & 300 Mg/15 Ml 40 mg, 100 mg, 300 mg Solution for infusion professional information leaflet below is the property of Hetero Drugs South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
